Lymphangioleiomyomatosis
Drug research and approvals for lymphangioleiomyomatosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 9 studies of lymphangioleiomyomatosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 4 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 9
- Trials authorized in Canada: 0
- FDA orphan approvals: 4
- EU medicines: 0
- Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and…NCT07304856 · Not reported · University of Milan · starts Apr 16, 2025
- Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)NCT06889168 · Phase 1 · Columbia University · starts Oct 20, 2025
- The Genotype and Phenotype of LymphangioleiomyomatosisNCT06405997 · Not reported · National Taiwan University Hospital · starts May 10, 2024
- Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)NCT06160310 · Not reported · David M. Ritter · starts Jul 1, 2023
- TSC Biosample Repository and Natural History DatabaseNCT05676099 · Not reported · National Tuberous Sclerosis Association · starts Jan 1, 2016
- Safety and Durability of Sirolimus for Treatment of LAMNCT02432560 · Not reported · University of Cincinnati · starts Mar 1, 2015
- Nebulized or Inhaled Albuterol for LymphangioleiomyomatosisNCT01799538 · Phase 1 / Phase 2 · National Heart, Lung, and Blood Institute (NHLBI) · starts Jun 10, 2013
- National Lymphangioleiomyomatosis Registry, FranceNCT01484236 · Not reported · Vincent COTTIN · starts Jan 1, 2012
- Study of the Disease Process of LymphangioleiomyomatosisNCT00001465 · Not reported · National Heart, Lung, and Blood Institute (NHLBI) · starts Dec 18, 1995
Phase 3 1
- SirolimusFK506-binding protein 1A inhibitor
Phase 2 7
- EverolimusFK506-binding protein 1A inhibitor
- SaracatinibTyrosine-protein kinase ABL inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- LoratadineHistamine H1 receptor antagonist
- LetrozoleCytochrome P450 19A1 inhibitor
- NintedanibPlatelet-derived growth factor receptor inhibitor
- Resveratrol
Phase 1 or earlier 3
- AlbuterolBeta-2 adrenergic receptor agonist
- ImatinibTyrosine-protein kinase ABL inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
How its trials ended
47 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 11 whose ending is known, 73% met their primary endpoint, 9% missed it and 18% stopped early.
- Completed, result not reported1838%
- Ongoing1430%
- Met its primary endpoint817%
- Status unknown49%
- Missed its primary endpoint12%
- Stopped: sponsor or business decision12%
- Stopped: other or unclear12%
| Apr 10, 2018 | AfinitorFor the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated… | Novartis Pharmaceuticals Corp. | Approved |
| May 28, 2015 | RapamuneTreatment of lymphangioleiomyomatosis (LAM) | Pfizer, Inc. | Approved |
| Apr 26, 2012 | AfinitorTreatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. | Novartis Pharmaceuticals Corp. | Approved |
| Oct 29, 2010 | AfinitorTreatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic… | Novartis Pharmaceuticals Corp. | Approved |
| Nov 17, 2014 | SirolimusTreatment of lymphangioleiomyomatosis | Cote Orphan Consulting, LLC | Designated |
| Jun 25, 2014 | SirolimusTreatment of lymphangioleiomyomatosis | LAM Therapeutics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA